Market Research Logo

Angina (Angina Pectoris) - Pipeline Review, H2 2015

Angina (Angina Pectoris) - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Angina (Angina Pectoris) - Pipeline Review, H2 2015’, provides an overview of the Angina (Angina Pectoris)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Angina (Angina Pectoris), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Angina (Angina Pectoris) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Angina (Angina Pectoris)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Angina (Angina Pectoris) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Angina (Angina Pectoris) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Angina (Angina Pectoris) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Angina (Angina Pectoris)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Angina (Angina Pectoris) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Angina (Angina Pectoris) Overview
Therapeutics Development
Pipeline Products for Angina (Angina Pectoris) - Overview
Angina (Angina Pectoris) - Therapeutics under Development by Companies
Angina (Angina Pectoris) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Angina (Angina Pectoris) - Products under Development by Companies
Angina (Angina Pectoris) - Companies Involved in Therapeutics Development
Baxalta Incorporated
Bayer AG
Cardiolynx AG
Gilead Sciences, Inc.
Juventas Therapeutics, Inc.
Kuhnil Pharmaceutical Co., Ltd.
Lacer, S.A.
Lee's Pharmaceutical Holdings Limited
LegoChem Biosciences, Inc
Milestone Pharmaceuticals, Inc.
Taxus Cardium Pharmaceuticals Group Inc.
ViroMed Co., Ltd.
Angina (Angina Pectoris) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
aladorian sodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
alferminogene tadenovec - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BAY-606583 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CLC-1201 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CLC-1280 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
eleclazine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JVS-100 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KI-1007 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LA-419 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LA-8045 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MSP-2017 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Activate Soluble Guanylate Cyclase for Angina Pectoris - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit Blood Factor XIa for CAHD and Stroke - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Antagonize Ryanodine Receptor 2 for Ventricular Arrhythmia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stem Cell Therapy for Cardiovascular Diseases - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VM-202 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ZK-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Angina (Angina Pectoris) - Recent Pipeline Updates
Angina (Angina Pectoris) - Dormant Projects
Angina (Angina Pectoris) - Discontinued Products
Angina (Angina Pectoris) - Product Development Milestones
Featured News & Press Releases
Jan 27, 2015: Taxus Cardium Announces Scientific Presentation And Clinical Update On Phase 3 Angiogenic Gene Therapy At The 2015 Phacilitate 11th Annual Cell & Gene Therapy Forum
Aug 13, 2014: Cardium Announces Review in Journal Of Cardiovascular Pharmacology Finds Gene Therapy For Subset Of Heart Disease Patients 'Highly Warranted'
May 09, 2014: Gilead Announces Phase 1 Data for Investigational Therapy, GS-6615, in Patients with Long QT-3 Syndrome
May 02, 2013: Cardium Therapeutics Announces Publication Of Data On Generx In Journal Molecular Therapy
Nov 19, 2012: Cardium Therapeutics Announces Patent Award for Rights to Cardiovascular Gene Therapy For Treatment Of Heart Disease
Sep 20, 2012: Cardiolynx Receives Patent For Improved Angina Pectoris Drug CLC-1280
Jul 07, 2011: Phase Two Study Suggests Use Of Adult Autologous Stem Cells May Improve Cardiac Function In Angina Patients
Apr 18, 2011: Lee’s Pharma Completes Phase I Study Of Anti-Platelet Drug Declotana
Nov 03, 2010: Cardium Awarded Grant Under QTDP Program
Oct 23, 2007: Announcement of supplemental approval of indication of Sigmart Injection, a treatment drug for unstable angina pectoris
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Angina (Angina Pectoris), H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Angina (Angina Pectoris) - Pipeline by Baxalta Incorporated, H2 2015
Angina (Angina Pectoris) - Pipeline by Bayer AG, H2 2015
Angina (Angina Pectoris) - Pipeline by Cardiolynx AG, H2 2015
Angina (Angina Pectoris) - Pipeline by Gilead Sciences, Inc., H2 2015
Angina (Angina Pectoris) - Pipeline by Juventas Therapeutics, Inc., H2 2015
Angina (Angina Pectoris) - Pipeline by Kuhnil Pharmaceutical Co., Ltd., H2 2015
Angina (Angina Pectoris) - Pipeline by Lacer, S.A., H2 2015
Angina (Angina Pectoris) - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2015
Angina (Angina Pectoris) - Pipeline by LegoChem Biosciences, Inc, H2 2015
Angina (Angina Pectoris) - Pipeline by Milestone Pharmaceuticals, Inc., H2 2015
Angina (Angina Pectoris) - Pipeline by Taxus Cardium Pharmaceuticals Group Inc. , H2 2015
Angina (Angina Pectoris) - Pipeline by ViroMed Co., Ltd., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Angina (Angina Pectoris) Therapeutics - Recent Pipeline Updates, H2 2015
Angina (Angina Pectoris) - Dormant Projects, H2 2015
Angina (Angina Pectoris) - Dormant Projects (Contd..1), H2 2015
Angina (Angina Pectoris) - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Angina (Angina Pectoris), H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Molecule Types, H2 2015
Number of Products by Stage and Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report